康方生物（AKESO）正加速推进其IO2.0与ADC2.0的融合战略。近日，该公司宣布，其针对Trop2/Nectin-4双特异性抗体偶联药物（ADC）AK146D1，联合旗下核心产品依沃西单抗（Ivonescimab），用于乳腺癌治疗的II期临床研究，已成功完成首例患者给药。
这一里程碑事件，标志着康方生物在探索新型联合疗法、攻克实体瘤领域迈出了关键一步。该研究聚焦于评估这种双特异性ADC与PD-1/VEGF双抗联用的安全性、耐受性及初步疗效。相较于传统疗法，这一组合策略旨在通过双重靶向与免疫激活，实现更精准、更强大的抗肿瘤效应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.